Show simple item record

dc.contributor.authorPiccart-Gebhart, MJ
dc.contributor.authorAftimos, PG
dc.contributor.authorDuhoux, FP
dc.contributor.authorWildiers, H
dc.contributor.authorIsambert, N
dc.contributor.authorCampone, M
dc.contributor.authorTosi, D
dc.contributor.authorVarga, AI
dc.contributor.authorBoni, V
dc.contributor.authorDoger, B
dc.contributor.authorCorbacho, JG
dc.contributor.authorJimenez-Rodriguez, B
dc.contributor.authorBorrego, MR
dc.contributor.authorSaura, C
dc.contributor.authorArkenau, HT
dc.contributor.authorWardley, Andrew M
dc.contributor.authorTroconiz, IF
dc.contributor.authorBinaschi, M
dc.contributor.authorSimonelli, C
dc.contributor.authorPellacani, AU
dc.date.accessioned2019-11-19T16:01:07Z
dc.date.available2019-11-19T16:01:07Z
dc.date.issued2019en
dc.identifier.citationPiccart-Gebhart MJ, Aftimos PG, Duhoux FP, Wildiers H, Isambert N, Campone M, et al. B-PRECISE-01 Study: a phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab � fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer. J Clin Oncol. 2019;37(15_suppl):TPS1101-TPS.en
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.TPS1101en
dc.identifier.urihttp://hdl.handle.net/10541/622462
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.15_suppl.TPS1101en
dc.titleB-PRECISE-01 Study: a phase lb trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab +/- fulvestrant for the treatment of HER2-positive advanced or metastatic breast canceren
dc.typeMeetings and Proceedingsen
dc.contributor.departmentInstitut Jules Bordet, Universit� Libre de Bruxelles, Brussels, Belgiumen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record